| 1 |
Creativity and the cybernetics of self: Drama, embodied creation and feedback processes
|
|
|
|
In: Davis, S, (2018). Creativity and the cybernetics of self: Drama, embodied creation and feedback processes. Burgoyne, S (Ed.), Creativity in theatre: Theory and action in theatre/drama education, p. 169-187Cham, Switzerland: Springer http://dx.doi.org/10.1007/978-3-319-78928-6_11 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 2 |
Performing the castaway
|
|
|
|
In: Davis, S, (2018). Performing the castaway. New Writing, Vol. 15, No. 2, p. 264-272 http://dx.doi.org/10.1080/14790726.2017.1417448 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 3 |
Inviting end-of-life talk in initial CALM therapy sessions: A conversation analytic study
|
|
|
|
In: Patient Education and Counselling , 100 (2) pp. 259-266. (2016) (2016)
|
|
BASE
|
|
Show details
|
|
|
| 4 |
Scores on Riley's stuttering severity instrument versions three and four for samples of different length and for different types of speech material.
|
|
|
|
In: Clin Linguist Phon , 28 (12) 912 - 926. (2014) (2014)
|
|
BASE
|
|
Show details
|
|
|
| 5 |
Basal insulin and cardiovascular and other outcomes in dysglycemia.
|
|
Gerstein, H.C.; Bosch, J.; Dagenais, G.R.; Díaz, R.; Jung, H.; Maggioni, A.P.; Pogue, J.; Probstfield, J.; Ramachandran, A.; Riddle, M.C.; Rydén, L.E.; Yusuf, S.
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 319-328 (2012)
|
|
Abstract:
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
|
|
Keyword:
Aged; Blood Glucose/analysis; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/etiology; Cholesterol/blood; Combination; Diabetes Mellitus; Double-Blind Method; Drug Therapy; Fasting; Fatty Acids; Female; Follow-Up Studies; Glucose Intolerance/complications; Glucose Intolerance/drug therapy; Hospitalization; Humans; Hypoglycemia/chemically induced; Hypoglycemic Agents/adverse effects; Hypoglycemic Agents/therapeutic use; Incidence; Insulin; Intention to Treat Analysis; Long-Acting/adverse effects; Long-Acting/therapeutic use; Male; Middle Aged; Omega-3/therapeutic use; Proportional Hazards Models; Triglycerides/blood; Type 2/complications; Type 2/drug therapy
|
|
URL: https://doi.org/10.1056/NEJMoa1203858
https://serval.unil.ch/notice/serval:BIB_24F963809D9F
|
|
BASE
|
|
Hide details
|
|
|
| 6 |
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
|
|
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 309-318 (2012)
|
|
BASE
|
|
Show details
|
|
|
| 7 |
Comparison of alternative methods for obtaining severity scores of the speech of people who stutter
|
|
|
|
In: CLIN LINGUIST PHONET , 25 (5) 368 - 378. (2011) (2011)
|
|
BASE
|
|
Show details
|
|
|
| 8 |
The effects of bilingualism on speakers who stutter during late childhood
|
|
|
|
BASE
|
|
Show details
|
|
|
| 9 |
The effects of bilingualism on stuttering during late childhood
|
|
|
|
BASE
|
|
Show details
|
|
|
| 10 |
The University College London Archive of Stuttered Speech (UCLASS)
|
|
|
|
In: J SPEECH LANG HEAR R , 52 (2) 556 - 569. (2009) (2009)
|
|
BASE
|
|
Show details
|
|
|
| 11 |
The effects of bilingualism on stuttering during late childhood
|
|
|
|
In: ARCH DIS CHILD , 94 (1) 42 - 46. (2009) (2009)
|
|
BASE
|
|
Show details
|
|
|
| 12 |
Stuttering and bilingualism: A reply to Packman, Onslow, Reilly, Attansio, Shenker
|
|
|
|
In: Archives of Disease in Childhood (2009) (2009)
|
|
BASE
|
|
Show details
|
|
|
| 13 |
The effects of bilingualism on speakers who stutter during late childhood
|
|
|
|
In: Archives of Disease in Childhood , 94 pp. 42-46. (2009) (2009)
|
|
BASE
|
|
Show details
|
|
|
| 14 |
The effects of bilingualism on stuttering during late childhood
|
|
|
|
BASE
|
|
Show details
|
|
|
| 15 |
Structural and functional abnormalities of the motor system in developmental stuttering.
|
|
|
|
In: Symplectic Elements at Oxford ; Europe PubMed Central ; PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) ; Web of Science (Lite) (http://apps.webofknowledge.com/summary.do) ; Scopus (http://www.scopus.com/home.url) ; CrossRef (2008)
|
|
BASE
|
|
Show details
|
|
|
| 16 |
Structural and functional abnormalities of the motor system in developmental stuttering
|
|
|
|
In: BRAIN , 131 50 - 59. (2008) (2008)
|
|
BASE
|
|
Show details
|
|
|
| 17 |
Late childhood stuttering
|
|
|
|
In: J SPEECH LANG HEAR R , 51 (3) 669 - 687. (2008) (2008)
|
|
BASE
|
|
Show details
|
|
|
| 18 |
Late childhood stuttering.
|
|
|
|
In: J Speech Lang Hear Res , 51 (3) pp. 669-687. (2008) (2008)
|
|
BASE
|
|
Show details
|
|
|
| 19 |
Structural and functional abnormalities of the motor system in developmental stuttering
|
|
|
|
In: In: (pp. pp. 50-59). (2008) (2008)
|
|
BASE
|
|
Show details
|
|
|
| 20 |
Plasticity in Recovery and Persistence of Stuttering
|
|
|
|
In: In: Plasticity and Speech Perception. (2005) (2005)
|
|
BASE
|
|
Show details
|
|
|
|
|
